Exelixis (EXEL) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free EXEL Stock Alerts $23.70 +0.17 (+0.72%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineThe Top 3 Biotech Stocks to Buy in April 2024investorplace.com - April 27 at 7:00 AMExelixis, Inc. (NASDAQ:EXEL) Holdings Raised by California Public Employees Retirement Systemmarketbeat.com - April 27 at 6:25 AMExelixis, Inc. (NASDAQ:EXEL) to Post Q2 2024 Earnings of $0.29 Per Share, Leerink Partnrs Forecastsamericanbankingnews.com - April 27 at 2:20 AMBrokers Issue Forecasts for Exelixis, Inc.'s Q2 2024 Earnings (NASDAQ:EXEL)marketbeat.com - April 26 at 8:48 AMExelixis, Inc. (EXEL)finance.yahoo.com - April 25 at 11:08 PMabrdn plc Invests $16 Million in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - April 25 at 6:15 AMGlobal Colorectal Cancer Pipeline Insights Report for 2024: An In-Depth Analysis of Clinical and Nonclinical Developmentsfinance.yahoo.com - April 23 at 7:33 PMExelixis (EXEL) to Release Earnings on Tuesdaymarketbeat.com - April 23 at 6:32 AM67,884 Shares in Exelixis, Inc. (NASDAQ:EXEL) Acquired by Calamos Advisors LLCmarketbeat.com - April 22 at 6:14 AMGlobal Liver Cancer Drug Market Size To Worth USD 7.6 Billion By 2033 | CAGR Of 10.90%finance.yahoo.com - April 18 at 9:56 AMLouisiana State Employees Retirement System Makes New $2.09 Million Investment in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - April 18 at 5:56 AMInstitutional investors in Exelixis, Inc. (NASDAQ:EXEL) lost 3.8% last week but have reaped the benefits of longer-term growthfinance.yahoo.com - April 17 at 2:01 PMExelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024businesswire.com - April 16 at 4:05 PMNewEdge Wealth LLC Purchases 212,553 Shares of Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - April 12 at 9:14 PMExelixis slips as Barclays downgrades on lack of catalystsmsn.com - April 11 at 1:50 PMExelixis (NASDAQ:EXEL) Shares Down 3.9% marketbeat.com - April 11 at 12:45 PMBarclays Lowers Exelixis (NASDAQ:EXEL) to Equal Weightmarketbeat.com - April 11 at 8:11 AMRyvu Therapeutics Presents Preclinical Data on RVU120 and Synthetic Lethality Programs at the 2024 AACR Annual Meetingfinance.yahoo.com - April 10 at 2:54 PMWhat Analysts Are Saying About Exelixis Stockmarkets.businessinsider.com - April 10 at 2:54 PM3 Biotech Gems Poised for April Breakthroughsstocknews.com - April 10 at 1:02 PMBuy Rating for Exelixis Amidst Positive Litigation Outlook and Cabozantinib Sales Performancemarkets.businessinsider.com - April 10 at 8:22 AMExelixis, Inc. (NASDAQ:EXEL) Forecasted to Earn Q1 2024 Earnings of $0.22 Per Sharemarketbeat.com - April 10 at 8:12 AMDekaBank Deutsche Girozentrale Buys 136,194 Shares of Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - April 10 at 5:51 AMQ4 2024 EPS Estimates for Exelixis, Inc. (NASDAQ:EXEL) Decreased by Analystmarketbeat.com - April 9 at 6:09 AMAdvisors Preferred LLC Takes $3.38 Million Position in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - April 5 at 5:35 PMExelixis, Inc.: No-Moat Exelixis Faces Cabozantinib Patent Losses; Early-Stage Pipeline Makes Progressfinance.yahoo.com - April 5 at 3:56 AM434,099 Shares in Exelixis, Inc. (NASDAQ:EXEL) Bought by Braun Stacey Associates Inc.marketbeat.com - April 4 at 8:48 AMSG Americas Securities LLC Trims Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - April 3 at 4:18 AMShort Interest in Exelixis, Inc. (NASDAQ:EXEL) Decreases By 6.8%marketbeat.com - April 1 at 6:39 AMExelixis: Patent Woes And Challenging Market Dynamics Make For A Testy 2024seekingalpha.com - March 28 at 2:54 PMBMO chief strategist sees buying opportunity for these U.S. stockstheglobeandmail.com - March 28 at 9:48 AMBuy Rating Affirmed on Kyverna Therapeutics Amid Anticipated Clinical Updates and Strong Financial Positionmarkets.businessinsider.com - March 28 at 9:48 AMExelixis, Inc. (NASDAQ:EXEL) Shares Sold by Assenagon Asset Management S.A.marketbeat.com - March 26 at 1:57 PMAlan M. Garber Sells 19,205 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stockinsidertrades.com - March 26 at 4:32 AMVanguard Group Inc. Reduces Position in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - March 22 at 4:45 AMExelixis, Inc.'s (NASDAQ:EXEL) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?finance.yahoo.com - March 21 at 10:20 AMAmerican Century Companies Inc. Purchases 338,021 Shares of Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - March 19 at 4:43 AMExelixis, Inc. (NASDAQ:EXEL) Holdings Boosted by Teachers Retirement System of The State of Kentuckymarketbeat.com - March 17 at 5:26 AMExchange Traded Concepts LLC Increases Holdings in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - March 16 at 7:20 AMExelixis, Inc. (NASDAQ:EXEL) Shares Sold by Meditor Group Ltdmarketbeat.com - March 14 at 11:51 AMRyvu Therapeutics Summarizes 2023 Fiscal Year and Provides Corporate Updatefinanznachrichten.de - March 13 at 10:34 AMPolar Capital Holdings Plc Has $23.31 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - March 12 at 10:35 AMExelixis, Inc. (NASDAQ:EXEL) Receives Average Recommendation of "Moderate Buy" from Analystsmarketbeat.com - March 11 at 4:19 AMJacobs Levy Equity Management Inc. Lowers Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - March 10 at 10:59 AM2 Biotech Stocks to Buy Hand Over Fist in Marchfool.com - March 8 at 8:15 AM10 Mid-Cap Stocks with Insider Purchasesfinance.yahoo.com - March 7 at 10:18 AM3 Cutting-Edge Biotech Stocks Sitting on the Brink of Successinvestorplace.com - March 6 at 4:45 PMKrensavage Asset Management LLC Sells 234,552 Shares of Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - March 6 at 12:20 PMExelixis, Inc.: Exelixis Earnings: Cabometyx Posts Strong Sales; Early-Stage Pipeline Makes Progressfinance.yahoo.com - March 5 at 5:41 AMAlberta Investment Management Corp Lowers Stake in Exelixis, Inc. (NASDAQ:EXEL)marketbeat.com - March 4 at 9:38 AM Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad)The latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. EXEL Media Mentions By Week EXEL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼0.490.32▲Average Medical News Sentiment EXEL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼127▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Halozyme Therapeutics News Repligen News Medpace News Charles River Laboratories International News National Research News Neurocrine Biosciences News Vaxcyte News Revolution Medicines News CRISPR Therapeutics News Qiagen News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
